FN2 Earnings Intelligence
Pfizer Inc. earnings overview
Latest Pfizer Inc. (PFE) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Pfizer Inc.
Pfizer's Q2 update strengthened the near-term growth case through a revenue beat, higher full-year revenue guidance, acquired-product growth and cost savings. The longer-term case remains dependent on pipeline execution, regulatory approvals, management of legacy-product losses and the durability of non-COVID growth.
Pfizer Inc.
Pfizer's Q1 2026 results show the post-COVID turnaround continuing to build momentum. Revenue of $14.5B and adjusted EPS of $0.75 both exceeded consensus, driven by 22% operational growth in the launched and acquired portfolio led by Padcev, Nurtec, Eliquis, and Vyndamax. Legal settlements extending Vyndamax exclusivity to mid-2029 and a Belgian court ruling on Comirnaty improve cash-flow visibility and support a high-single-digit CAGR starting 2029. Management reaffirmed full-year guidance and highlighted roughly 20 pivotal study starts, 8 key readouts, and 4 regulatory decisions planned for 2026. Despite the beat, the stock saw a modest negative abnormal return on report day and has drifted approximately 4.2% lower subsequently, suggesting the market remains cautious about LOE pressures through 2028 and the 2028 timeline for the first obesity approval.
Pfizer Inc.
The supplied analysis supports a constructive but conditional view of Pfizer's forward trajectory: pipeline progress, non-COVID portfolio resilience, and productivity efforts are positive, while regulatory execution, patent pressure, and competition remain material offsets.
Pfizer Inc.
Pfizer's Q3 analysis supports a mixed thesis: raised EPS guidance, non-COVID portfolio growth, pipeline progress and targeted cost savings provide support, but COVID-19 decline, pricing pressure, transaction execution and regulatory dependencies remain material offsets.
Pfizer Inc.
The current analysis supports a constructive view of Pfizer's near-term earnings trajectory: management reported growth and margin progress, raised EPS guidance, and highlighted pipeline catalysts. The thesis is tempered by policy uncertainty, vaccine-demand volatility, competition, and execution risk.
Get the PFE recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.